ASCO Puts A Spotlight On CDK4/6 Category Ahead Of New Competition
Executive Summary
Data to be presented at the American Society of Oncology meeting in June on cyclin-dependent kinase 4/6 inhibitors, an important new category of drugs to treat breast cancer, suggest Pfizer Inc. is well positioned to maintain its lead in the category even as new competition prepares to enter the market.
You may also be interested in...
Ibrance Trial Cements CDK4/6 Inhibitors As Standard Of Care In Breast Cancer
New England Journal of Medicine editorial sings the praises of CDK4/6 inhibitors in breast cancer, which include Pfizer's Ibrance, Novartis's ribociclib and Elli Lilly's abemaciclib.
Lilly's Abemaciclib Hit Leaves It Down But Not Out
Continuation of Phase III MONARCH 2 study, with no early termination for efficacy, may mean a delay in filing and a tougher competitive outlook against Pfizer's Ibrance and Novartis' ribociclib.
2Q Pharma Results Preview: What Lies Ahead
The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.